Five-year follow-up of patients with difficult-to-treat rheumatoid arthritis
An erratum to this article was published (Rheumatology (Oxford), 1 Jun 2025 ↗)
Authors' conclusion
Further modifications in RA treatment are useful for resolving D2T RA. Multiple comorbidities and glucocorticoid use are associated with mortality.
Study context
- Population
- Patients identified as D2T RA in 2018, followed until 2023150 analysed
- Participants
- 173 patients
- Exposure
- Resolved D2T RA vs persistent D2T RA vs mortality at last visit
- Resolved D2T RAn = 67
- Persistent D2T RAn = 75
- Diedn = 8
- Outcome
- Outcome at last visit: resolved D2T RA, persistent D2T RA or mortality
- Follow-up
- 2023
Methodological detailsfive-year follow-up
- Five-year follow-up
Main finding
As reported in the abstract
Outcome at last visit
Observational data: associations, not effects.
Further findings
Independent risk factors for mortality
| OR | P value | |
|---|---|---|
| Rheumatic disease comorbidity index | 3.50 | P = 0.02 |
| GC dose escalation | 31.9 | P = 0.002 |
Characteristics of resolved vs persistent D2T RA or died
- Younger at latest visit
- P = 0.02
- Higher proportion of treatment changes during five years
- P = 0.002
- Higher proportion of IL-6R inhibitor use in 2023
- P = 0.04
Resolution in patients with multidrug resistance
- D2T RA resolved, mainly with treatment changes
- 38%
Original publication
Five-year follow-up of patients with difficult-to-treat rheumatoid arthritis. Rheumatology (Oxford). Published 8 June 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →